Novartis gets an option to Transgene's TG4010; option not exercised
Novartis licensed the exclusive option to globally develop and market Transgene SA's (immunotherapies for cancer and infectious disease; part of Institut Merieux) TG4010 (MVAMUC1IL2). The compound is ready to begin Phase IIb/III trials as a first-line treatment for MUCI-positive non-small cell lung cancer (NSCLC) and other types of cancer.
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.